Related Experiment Video

Updated: May 20, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

[Oligometastatic hormone-sensitive prostate cancer: when can less be more?]

Richard Cathomas1

  • 1Abteilung Onkologie/Hämatologie, Kantonsspital Graubünden, 7000, Chur, Schweiz. richard.cathomas@ksgr.ch.

Urologie (Heidelberg, Germany)
|May 18, 2026
PubMed
Summary

Modern imaging detects more prostate cancer with low tumor burden. While metastasis-directed therapy (MDT) and intermittent androgen deprivation therapy (ADT) show promise for oligometastatic prostate cancer, clinical trials are ongoing to confirm benefits.

Keywords:
Androgen deprivationMetastasisPSMA PET-CTProstate-specific antigenSystemic therapy

More Related Videos

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

An Orthotopic Murine Model of Human Prostate Cancer Metastasis06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

Related Concept Videos